Article

 

A ROS-activatable agent elicits homologous recombination DNA repair and synergizes with pathway compounds Open Access Deposited

Downloadable Content

Download PDF
Download Adobe Acrobat Reader
Date Uploaded: 03/03/2017
Date Modified: 04/07/2017

We have designed ROS-activated cytotoxic agents that are active against AML cancer cells. In this study the mechanism and synergistic effects against cells co-expressing the AML oncogenes MLL-AF9 fusion and FLT3-ITD was investigated. The agent had an IC50 value of 1.8±0.3 μM with a selectivity of 9-fold compared to untransformed cells. Treatment induced DNA strand breaks, apoptosis, and cell cycle arrest. Proteomics and transcriptomics revealed enhanced expression of the pentose phosphate pathway, DNA repair, and pathways common to cell stress. Western blotting confirmed repair by homologous recombination. Importantly, RAC1 treatment was synergistic in combination with multiple pathway targeting therapies in AML cells but less so in untransformed cells. Taken together, these results demonstrate that RAC1 can selectively target poor prognosis AML and do so by creating DNA double strand breaks that require homologous recombination.

Creator
License
Subject
Submitter
College
Department
Date Created
Journal Title
  • ChemBioChem
Language
Note
  • This work was part of a pilot "mediated-deposit model" where library staff found potential works, later submitted for faculty review

Digital Object Identifier (DOI)

Identifier: 10.1002/cbic.201500304
Link: http://dx.doi.org/10.1002/cbic.201500304

This DOI link is the best way for others to cite your work.

Relationships

Items

Permanent link to this page: https://scholar.uc.edu/show/bc387093q